



# ADVANCES IN THERAPY OF DENGUE HEMORRHAGIC FEVER

*ENDOCRINE TECHNOLOGY L.L.C. INVITES Collaborations from Life Science Stack Holders*

BROOKLYN, NY, USA, December 11, 2017 /EINPresswire.com/ -- Endocrine Technology, L.L.C. is New York based Biotechnology Company that advances therapy of "[Dengue Hemorrhagic Fever](#)". Dengue is the most important global threat of Mosquito based viral disease. It is an endemic disease in over 120 countries. At the time of monsoon, the number of cases increase dramatically to assume the form of Epidemic. It is also a pandemic disease due to rapid travel and global warming effects. At risk are 3 Billion people. 300 M people are hospitalized annually and 30,000 people die annually from "[Dengue Hemorrhagic Fever](#)" (DHF) and Dengue Shock Syndrome (DSS). Currently there are no drug therapies or effective vaccine. This leads to overcrowding of hospitals, inadequate treatment and it is associated with high cost, social and political backlash. Thus for example, a single patient died in India, the cost of therapy in a super specialty hospital was Rs. 1.8 Million for 15 days therapy. The hospital cost globally to take care of "Dengue Hemorrhagic Fever" is expected to be very high. The underlying cause is the knowledge gap amongst stack holders in life sciences about the Recent Advances in Genomics and Fundamentals of Immunology.

Endocrine Technology, L.L.C. fulfills this knowledge gap and advances therapy for Dengue Hemorrhagic Fever from concept to bedside application.

In the link below

<http://www.onemedplace.com/database/list/cid/15400>

there are two presentations 1. Press Release and 2. Webcast on Atypical Hemolytic Uremia Syndrome.

This link explains the advances in genomics and fundamentals of immunology made by Endocrine Technology, L.L.C. and why such advances will contribute to success in Dengue hemorrhagic fever. In the upcoming website: [www.etdengue.com](http://www.etdengue.com), the company has disclosed draft label with human safety data along with clinical studies at the bottom link.

In the section learn more, there is presentation given for dengue hemorrhagic fever.

Endocrine Technology is of the opinion that frank sharing of scientific advances will lead to collaborative efforts amongst all stack holders of Life science industry and will lead to expedient advances in genomics and Fundamentals of Immunology. These advances can be applied strategically to develop novel products from concept to bedside for the therapy dengue hemorrhagic fever. The Company has approved patents in both USA and India.

Kumarpal A. Shah  
Endocrine Technology, LLC  
7182221065  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.